Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
HemaSphere · 2025-09 · 9 (9)
DOI: 10.1002/hem3.70207 ↗Kurz gefasst
Leitlinie in der Zeitschrift HemaSphere, online erschienen am 23.09.2025. Verfasst von Catherine Thieblemont und 22 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité Paris France. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Large B‐cell lymphoma (LBCL) accounts for about one‐third of adult lymphoma cases. Diagnosis requires specialized hematopathology laboratories, with immunophenotypic analysis essential for confirming B‐cell lineage and identifying variants. MYC and BCL2 rearrangements indicate a poor prognosis. Staging and prognosis rely on positron emission tomography computed tomography (PET‐CT). The International Prognostic Index (IPI) aids risk stratification. PET‐CT is critical for assessing treatment response and guiding strategies. First‐line management for LBCL can be informed by interim PET to assess chemosensitivity, with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) or polatuzumab vedotin rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola‐R‐CHP) for advanced stages depending on IPI scores. Primary mediastinal B‐cell lymphoma (PMBCL) management favors R‐CHOP given every 14 days (R‐CHOP14) or dose‐adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab (DA‐EPOCH‐R) without radiotherapy in complete responders. Elderly patients, unfit or not (≥80 years or
Autor:innen und Institutionen
- Université Paris Cité Paris France.
- Hemato-oncologie Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis Paris France.
- Hematology Department Instituto Portugues de Oncologia Lisbon Portugal.
- University of Helsinki and Helsinki University Hospital Helsinki Finland.
- Hematology & Oncology University Hospital Münster Münster Germany.
- Assistance Publique - Hôpitaux de Paris, Hôpital Cochin Université Paris Paris France.
ORCID-Profile: Sirpa Leppä, Florence Broussais, Marie-José Kersten
Zitieren
APA
Thieblemont, C., Gomes Da Silva, M., Leppä, S., Lenz, G., Cottereau, A. S., Fox, C., Lopez-Guillermo, A., Illidge, T., Jurczak, W., Eich, H., Aurer, I., Trneny, M., Rosenwald, A. A., Davies, A., Zwezerijnen, B. G., Bolanos, N., Marković, M., Jais, J. P., Broussais, F., …, & Kersten, M. J. (2025). Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere, 9(9). https://doi.org/10.1002/hem3.70207
Vancouver
Thieblemont C, Gomes Da Silva M, Leppä S, Lenz G, Cottereau AS, Fox C, et al. Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere. 2025;9(9). doi:10.1002/hem3.70207
BibTeX
@article{Thieblemont2025,
author = {Thieblemont, Catherine and Gomes Da Silva, Maria and Leppä, Sirpa and Lenz, Georg and Cottereau, Anne-Ségolène and Fox, Christopher and Lopez-Guillermo, Armando and Illidge, Timothy and Jurczak, Wojciech and Eich, Hans and Aurer, Igor and Trneny, Marek and Rosenwald, Andy Andreas and Davies, Andrew and Zwezerijnen, Ben Gerben and Bolanos, Natacha and Marković, Maja and Jais, Jean-Philippe and Broussais, Florence and Dreyling, Martin and Vitolo, Umberto and Tilly, Hervé and Kersten, Marie-José},
title = {Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {9},
doi = {10.1002/hem3.70207}
}
EUVIMED